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INTRODUCTION 
During pregnancy, the human body undergoes several changes in 
the process of its adaptation to the growing foetus. Although these 
changes are physiological, there is potential for morbidity and mortality 
to both mother and foetus. Liver is the site of many important metabolic 
and synthetic functions of the body. Abnormal liver tests occur in 3%-5% 
of pregnancies. 
 
Jaundice affects a small percentage of pregnant women, yet it takes 
a major toll on health of both mother and foetus especially in developing 
countries like India. Jaundice in pregnant women has been estimated to 
cause 5-20% of maternal mortality and considerable percentage of 
perinatal wastage in India. 
 
Liver could be the target of diseases specific to the pregnancy such 
as intrahepatic cholestasis of pregnancy and acute fatty liver of 
pregnancy, and there are no available means by which to predict with 
certainty how and when such illnesses may occur. In addition, morbidity 
is more likely in the presence of a pre-existing liver disease as in auto 
immune hepatitis or when a new onset liver disease occurs during 
pregnancy. 
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Acute viral hepatitis is the most common cause of jaundice in 
pregnancy. The outcome is usually benign. Intervention might not be 
required except in cases of viral hepatitis E and herpes simplex hepatitis. 
Pregnant women with jaundice and acute viral hepatitis caused by HEV 
infection has a higher maternal mortality rate and worse obstetric and 
fetal outcomes than did pregnant women with jaundice and acute viral 
hepatitis caused by other types of viral hepatitis. 
Pregnancy is unusual in women with severe chronic liver disease. 
However, women with less severe disease or those with non cirrhotic 
portal hypertension do not have diminished fertility and may become 
pregnant.  
Pregnancy has a variable effect in women with cirrhosis and portal 
hypertension. Worsening jaundice with progressive liver failure, ascites, 
and hepatic coma can occur, but some women with cirrhosis can sustain 
pregnancy without any worsening of hepatic function. In addition, the 
incidence of stillbirths and premature deliveries may be increased.  
Pregnancy is generally well tolerated by women who are chronic 
carriers of hepatitis B virus. The overall risk of HBV transmission from 
the mother to infant is about 40 %. Transmission at birth is more likely if 
the mother is HBeAg positive or has high circulating levels of HBV 
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DNA. Prenatal screening of all pregnant women for HBsAg is now 
performed routinely in many countries. Neonates born to HBsAg positive 
women should receive hepatitis B immunoglobulin and HBV vaccine at 
birth, regardless of HBeAg status of the mother.  
However, when appropriately diagnosed and managed, the 
outcome may be favourable and the liver disease in pregnancy could 
resolve without any chronic consequences. Signs and symptoms of liver 
disease in pregnancy are not specific, but the underlying disorder can 
have significant morbidity and mortality effects on the mother and foetus. 
Early recognition can be lifesaving. 
Vigilance in recognizing liver disorders in pregnancy and early 
coordinated management among the primary care physician, obstetrician, 
and liver specialist are essential for promoting good maternal and fetal 
outcomes. 
Therefore this study is undertaken in Institute of Obstetrics and 
Gynaecology with an aim to analyse the cause of the disease, altered liver 
function, maternal and fetal morbidity and mortality and preventive 
measures. This study will help in better understanding and improving the 
maternal and perinatal outcome in jaundice complicating pregnancy. 
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AIMS AND OBJECTIVE 
 
• To evaluate the etiology of jaundice complicating pregnancy in 
patients of Institute of Obstetrics and Gynaecology. 
• To evaluate the maternal and fetal outcome of jaundice 
complicating pregnancy. 
• To evaluate the efficacy of prophylactic measures in the prevention 
of jaundice. 
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REVIEW OF LITERATURE 
CONCEPTS OF JAUNDICE 
 
Jaundice is the yellowish staining of the skin and sclera that is caused by 
high levels bilirubin in blood . Total value above 2.5 mg/dl  of  bilirubin is 
associated with clinical jaundice. 
 
Production & metabolism of bilirubin: 
Source of bilirubin: 
Reticulo endothelial system    Bone Marrow 
Destruction of senescent red cells Destruction of maturing red cells 
  80-85%     15-20% 
        HB 
   Heme   Globin Liver  
   Heme oxygenase  Turnover of heme 
   Biliverdin 
    Biliverdin reductase 
 
U  Unconjugated form is bound tightly to albumin in plasma 
Bilirubin 
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Hepatic metabolism of Bilirubin: 
Three phases 1. Hepatic uptake 
   2. Conjugation 
   3. Excretion into bile -rate limiting step 
Uptake and Conjugation: 
 Unconjugated bilirubin bound to albumin enters liver and the 
complex dissociates.  Non-polar bilirubin enters the hepatocyte and gets 
conjugated to glucuronic acid forming bilirubin glucuronide, which is 
water-soluble. Only conjugated bilirubin can be excreted into bile. 
BILIRUBIN METABOLISM 
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Intestinal phase of bilirubin metabolism: 
Conjugated bilirubin into bile 
Through biliary ducts into duodenum 
Conjugated bilirubin not reabsorbed by intestinal mucosa 
 
Excreted unchanged in stool Metabolized by ileal & colonic bacteria 
      Urobilinogen & related products 
      Reabsorbed from S.I & Colon 
 (Some) By passes the liver  Enters portal circulation 
  Excreted by kidney          Taken up by liver 
       Re excreted into bile 
Normal daily urinary excretion of urobilinogen does not exceed 4mg. 
 
Increased Excretion of Urobilinogen – Due to: 
1. Hepatic uptake & excretion is impaired in hepatocellular disease. 
2. Increase bilirubin production as in hemolysis. 
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Decrease Excretion of Urobilinogen – Due to: 
 Cholestasis 
 Extra hepatic biliary obstruction 
Renal excretion of bilirubin: 
 Normally there is no detectable bilirubin in urine.  Only conjugated 
bilirubin can be excreted.  Bile salts enhance glomerular filtration of 
conjugated bilirubin. 
 In cholestasis & extra hepatic biliary obstruction there is increasing 
circulating bile salts and increase in bilirubin excretion. 
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IMPORTANT FUNCTIONS OF THE LIVER 
 Bilirubin metabolism 
 Bile acid metabolism 
 Carbohydrate metabolism 
 Lipid metabolism 
 Xenobiotic metabolism 
 Protein synthesis  
 Immune function 
Changes in Liver During Pregnancy: 
Anatomical changes: 
 No alteration in liver weight occurs.  During III Trimester, liver 
occupies more postero superior position with displacement to right and 
reduction in dullness to percussion. 
 Hence detection of hepatomegaly is a strong evidence for the 
presence of liver disease. 
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Physiological Changes 
 Hepatic blood flow is maintained in pregnancy unaltered, resulting 
in a decline in the proportion of cardiac output delivered to liver by 35%.  
This is due to increase in plasma and blood volume by 50% and rise in 
cardiac output by 50%. 
 The relative decrease in hepatic blood flow may contribute to 
reduction in clearance of various compounds from blood. 
Protein metabolism: Synthesis of all serum proteins is affected.  Total 
serum protein concentration is decreased by 20% primarily due to fall in 
S.albumin.  This is due to 
1. Hemo dilution 
2. Increase in albumin catabolism. 
Serum α1, α2, β globulins – rise up to 50%. 
Bilirubin metabolism: 
 Slight rise in S.bilirubin in 5% pregnancy otherwise normal is 
reported, due to increased bile viscosity & histologically dilated biliary 
canaliculi. 
 Increase in S.bilirubin in pregnancy should be considered as 
presumptive evidence for presence of liver or hematological disorder. 
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Serum enzymes: 
 Total S.alkaline phosphatase is elevated more in III trimester, 
increases by 2-4 times normal, major source being placenta. 
 Gamma glutaryl transpeptidase, LDH are increased near term. 
SGOT & SGPT: 
 They are only slightly altered by normal pregnancy.  May rise near 
term, but within normal range. 
Physical examination — Spider angiomas and palmar erythema, which 
are classically associated with chronic liver disease, are also common 
during pregnancy and usually disappear after delivery. It is presumed that 
the hyperestrogenemia of pregnancy is responsible for these changes.  
 
LIVER FUNCTION TESTS 
In a case of jaundice complicating pregnancy, liver function tests  is done to 
- confirm the diagnosis 
- assess the severity of the disease  
- assess the prognosis 
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TESTS OF BILIARY EXCRETION 
1. Serum Bilirubin:Vandenberg’s method (1913) of spectrophotometric 
determination is used. 
Normal values are Total: 0.3-1 mg/ dl 
        Direct: 0.25 mg %( Conjugated bilirubin) 
                       Indirect: 0.75mg %(unconjugated bilirubin)  
If indirect bilirubin is more than 80% of total bilirubin, it is called 
predominantly unconjugated  hyperbilirubinemia.  
If direct bilirubin is more than 50% of total bilirubin, it is called 
predominantly conjugated  hyperbilirubinemia 
2. Urine bilirubin (Bile Pigments) 
This is estimated by modified fouchet’s test &Hay’s test. Bilirubinuria 
occurs when there is an increase in the serum conjugated bilirubin. So it is 
absent in hemolytic jaundice. Bilirubinuria occurs even with minimal liver 
damage and can be detected even before clinical manifestation. 
3. Urine urobilinogen 
It is detected by Ehrlichs Aldehyde test 
It is strongly positive in hemolytic jaundice. 
In viral hepatitis, it is positive during preicteric and convalescent phase but 
disappears during icteric phase. 
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II. TESTS OF METABOLIC FUNCTION 
1. Serum proteins: Serum proteins are estimated by precipitation of 
globulin with 23% sodium sulphate. The remaining protein in solution is 
taken as albumin. The normal serum proteins are Total: 6-8.5 gm/dl and 
globulin2.4-3.7 g/dl. Normal Albumin- Globulin ratio is 1.5. 
In diffuse parenchymal liver diseases albumin concentration falls and 
globulin fraction increases relatively. The albumin globulin ratio is reversed 
in such conditions. 
2. Serum alkaline phosphatase: Normal value is 5-15 KA units. It is 
synthesized by liver, bone, intestine, placenta, etc. So to be specific, 
electrophoretic separation of  isoenzymes of alkaline phosphatase is to be 
done. Marked rise occurs both in intrahepatic and extra hepatic cholestasis. 
Clotting factors  
Liver synthesizes the clotting factors II,V,VII,IX&X.  So in the presence 
of severe hepatocellular damage, 
1. Clotting time is prolonged (Normal 5-15 minutes). 
2. Prothrombin time is increased, It measure the factors involved in the 
2nd and 3rd stages of coagulation in extrinsic coagulation system. 
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III. TESTS OF LIVER CELL DAMAGE 
1. Serum Glutamic- pyruvic transaminases  (SGPT or ALT) 
SGPT is specifically associated with the liver parenchymal cells and 
released into the plasma in large amounts when the liver cells are damaged. 
Normal level of SGPT 5-35 IU/L. 
2. Serum Glutamic-Oxaloacetic transaminases  (SGPT or AST) 
     SGPT is associated with the liver, brain and heart tissues and released 
into the plasma in large amounts when these organs are damaged Normal 
level of   SGOT : 5-40 IU/L. 
3. Serum Gamma Glutamyltransferase  (SGGT) 
SGGT is associated with Alcoholism or Biliary stasis. 
 With parenchymal liver diseases, the aminotransferase enzymes are 
elevated sometimes to several hundreds. So estimation is needed for 
follow-up. In patients with acute fulminant hepatitis, serum 
aminotransferase may decrease due to previous excessive release of these 
enzymes and this is the omnious sign. 
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CLASSIFICATION OF JAUNDICE IN PREGNANCY 
 
Jaundice peculiar to pregnancy 
• Hyperemesis gravidarum 
• Intrahepatic cholestasis of pregnancy 
• HELLP syndrome 
• Acute fatty liver of pregnancy 
 
Jaundice superimposed on pregnancy 
• Viral hepatitis 
• Gall stone 
• Drug-induced hepatotoxicity 
• Haemolytic jaundice 
 
Pregnancy superimposed on liver diseases 
•Cirrhosis and portal hypertension 
•Wilson’s disease 
•Hepatitis B and C  
•Autoimmune liver disease 
 
 16 
 
JAUNDICE SUPERIMPOSED ON PREGNANCY 
CAUSES OF VIRAL HEPATITIS 
• Hepatitis A Virus 
• Hepatitis B Virus 
• Hepatitis C Virus 
• Hepatitis D Virus 
• Hepatitis E Virus 
Other uncommon viruses 
• Herpes simplex virus 
• Cytomegalovirus 
• Epstein Barr virus 
• Yellow fever virus 
Bacterial diseases 
• Leptospirosis 
• Typhoid fever 
• Gonococcal disease 
Parasites 
• Malaria        
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FEATURES OF THE MAIN HEPATITIS VIRUSES 
  
Hepatitis A HepatitisB Hepatitis C Hepatitis D Hepatitis  E 
Virus Group/ 
Nucleic Acid/ 
Size(diameter) 
Enterovirus 
RNA 
27nm 
Hepadno 
DNA 
42nm 
Flavi virus 
RNA 
30-38nm 
Incomplete 
RNA 
35nm 
Calci virus 
RNA 
27nm 
Incubation 
period(weeks) 2-4 4-20 2-26 6-9 3-8 
Seasonal 
Incidence Winter 
Year 
around 
Year 
around Year around Winter 
Age Children Any Any Any Any 
Spread 
1. Feco-oral 
2. Blood 
3. Sexual 
4. vertical 
 
Yes 
Uncommon 
Uncommon 
No 
 
No 
Yes 
Yes 
Yes 
 
 
No 
Yes 
Uncommon 
Uncommon 
 
 
No 
Yes 
Yes 
Yes 
 
 
Yes 
No 
? 
No 
 
 
Type of onset 
 
Acute 
 
Insidious 
 
 
Insidious 
 
Acute or 
Insidious Acute 
Fever common 
Less 
common 
 
Less 
common 
 
Less common 
 
common 
Carrier state No Yes (5-10%) Yes>50% Yes No 
Prognosis Good Worse with Age Moderate Same as HBV 
Good except 
In pregnancy 
Prevention 
Active 
Passive 
 
Vaccine 
immune 
serum 
globulin 
 
Vaccine 
Hyper 
immune 
Serum 
globulin 
 
No 
No 
 
Prevented by 
Prevention of 
Hepatitis B 
Virus 
infection 
 
 
Under trial 
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Clinical features of viral Hepatitis 
• Preicteric period 
- In Hepatitis A and Hepatitis E the onset is abrupt with fever but in 
Hepatitis B and Hepatitis C the onset is insidious. 
- The initial symptoms are loss of appetite, nausea, vomiting, lassitude, 
abdominal pain and diarrhea. 
- At the end of the period, the urine darkens. 
- The duration of this period varies from 1-21 days, average 5-7 days. 
• Icteric period 
- The urine deepens continuously and jaundice appears on the skin and 
sclera within 2 weeks. 
- Subjective symptoms abate. 
- Liver palpable in7%, spleen palpable in 20%. 
- The period lasts for 2-6 weeks. 
• Convalescent period 
- The jaundice disappears gradually. 
- Liver and spleen retract, liver function return to normal. 
- The period lasts 2 weeks to 4 months, average 1 month. 
- About 10% of Hepatitis B and 50% of Hepatitis C will become 
chronic hepatitis. 
- Acute hepatitis E is similar to acute hepatitis A, but cholestasis is 
obvious and symptoms and signs are severe. 
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Fulminant Hepatitis  
Development of hepatic encephalopathy within 8 weeks of initiation of 
symptoms in a patient without known chronic liver disease. 
All five kinds of hepatitis virus can cause this type of hepatitis. The 
incidence is only 0.2-0.5%, but the mortality is high.  
• The onset may begin in a typical acute icteric hepatitis, but 
within 10 days  
• Jaundice deepens rapidly 
• Vomit is frequent  
• Obvious anorexia  
• Hemorrhage 
• The liver shrinks in size with massive necrosis. 
• Prothrombin time is prolonged  
• Ascites appear 
• Acute renal failure  
• Hepatic encephalopathy    
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HEPATITIS A 
         Hepatitis A spread via the feco-oral route, and common in low 
socioeconomic areas. The hepatitis A infection during pregnancy is similar 
to that in nonpregnant patients.But gestational complications are 
common.[1]Vertical transmission has not been reported. Sexual and 
household contact  with hepatitis A is reported in about 10 % of cases.[2] 
Course of hepatitis A 
              
DIAGNOSIS — Acute HAV infection is detected by anti-HAV antibodies. 
It is seen at the onset of symptoms, peaks during the acute or early 
convalescent period, and it is present for 4 to 6months.IgG anti-HAV is 
detected early in the convalescent phase, and remains for years. 
TREATMENT—As the disease is self-limited, the treatment is 
symptomatic and supportive. 
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PREVENTION — Prevention is by proper hand washing, and drinking 
safe water. Chlorination inactivates the virus. Immunoglobulin (IG) 
prevents 80%-90% of cases of hepatitis A if it is given shortly after the 
infection or before exposure.[3] 
HEPATITIS B 
        Acute HBV infection do not increases mortality during pregnancy and 
it has no teratogenic effects. However, a higher incidence of low birth 
weight and prematurity has been reported. About 350 million individuals 
are chronically infected with hepatitis B virus (HBV) worldwide, and at 
least 50% of them acquired their infections either perinatally or in early 
childhood. Hence prevention of perinatal transmission is a high priority to 
decrease the global burden of chronic HBV. 
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 COURSE OF HEPATITIS B 
 
 
Acute infection is characterized initially by the presence of HBeAg. 
HBsAg and HBV DNA begins in the preclinical phase. IgM anti-HBc 
appears early in the clinical phase, the combination of IgM anti-HBc and 
HBsAg makes the diagnosis of acute infection. Recovery is accompanied 
by normalization of the serum ALT, the disappearance of HBV DNA, 
HBeAg to anti-HBe seroconversion, and subsequently HBsAg to anti-HBs 
seroconversion and switch from IgM to IgG anti-HBc. 
       Chronic infection is characterized by persistence of HBeAg (for a 
variable period), HBsAg, and HBV DNA in the circulation; anti-HBs is not 
seen. Persistence of HBsAg for more than six months after acute infection is 
considered indicative of chronic infection. 
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Interpretation of serology tests for hepatitis B.[4] 
Test Acute Hepatitis B 
Immunity 
following 
infection 
Immunity 
due to 
vaccination 
Chronic 
Hepatitis B
— Active 
Chronic 
Hepatitis B— 
Inactive 
Carrier 
HBsAg + – – + + 
Anti-HBs – + + – – 
HBeAg + – – +/– – 
Anti-HBe – +/– – +/– + 
Anti-HBc + + – + + 
IgM anti-
HBc + – – – – 
HBV 
DNA + – – + + (low) 
ALT Elevated Normal Normal Elevated Normal 
 
HBV Transmission[5] 
In utero (<10%) 
Associated with  
• Acute HBV in third trimester 
• Maternal HBeAg and high HBV DNA 
• History of threatened preterm labor 
  
At the time of delivery
• HBeAg-positive mothers: 85%
• HBeAg-negative mothers: 31%
• caesarean section does not prevent transmission
 
After birth 
• Breastfeeding not associated with transmission 
 
Risk of perinatal transmission
Post Exposure Prophylaxis (PEP):
• Dose 1 of Hep B vaccine in t
HBIG 0.5 ml in the opposite thigh IM within 12 hrs of birth but n
later than 7 days. 
• Dose 2 of hepatitis B vaccine at 1
B vaccine at 6 mon
total of 4 hep B doses 
24 
 
 
 
 
 
[6] 
  
he thigh within 12 hrs of
 
-2 months of age. Dose 3 of hepatitis 
ths of age. The Infant < 2000 gms should receive a 
.(Liver International 2009; 29 : 135 
 
  birth and 
ot 
-139) 
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• Active plus passive immunization is 95% effective and only Active 
immunization is 72% effective in preventing transmission. 
• Lamivudine 100mg /day given 1 month before delivery decreases 
HBV transmission from 28.0% to 12.5% .[7] 
• Post-vaccination testing (PVT) should be done in all infants after the 
third  dose of hepatitis B vaccine ideally at the  9 or 12 month visit. 
•  90% of infected infants become chronic carriers in the absence of post 
exposure prophylaxis. 
Hence, all antenatal patients should be screened universally for Hepatitis B 
and babies of positive mothers should receive both Active and Passive 
immunization. 
HEPATITIS E 
Hepatitis E virus (HEV) is transmitted feco-orally. Infection with Hepatitis 
E was first reported in 1955 in New Delhi, India.[8] Some patients have 
asymptomatic infection .Hepatitis E is more severe compared with hepatitis 
A especially in pregnant women.  
DIAGNOSIS — Acute infection is diagnosed by the presence of of IgM  
HEV antibodies in serum. Hepatitis E virus is detected in serum or stool by 
Polymerase chain reaction (PCR).Antibody tests against HEV are often 
associated with false positive and negative results. 
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Course of hepatitis E   
 
The incubation period after oral exposure is four to five weeks. HEV can be 
detected in stool one week before the onset of illness and it is present for 
two weeks. Because HEV is enterically transmitted, patients are infectious 
during fecal shedding. While HEV viremia is short-lived in most patients, it 
can persist for up to four months. 
IgM anti-HEV appears during early phase of clinical illness and disappears 
rapidly over four to five months. The IgG antibodies appears shortly after 
the IgM, remaining high from 1 to as long as 14 years.[9] 
PREGNANCY 
Hepatitis E infection results in fulminant hepatic failure and high mortality 
in 15 - 25 %pregnant women. Pregnancy with an altered status of sex 
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steroid hormones and reduced immunocompetence predisposes to increased 
viral replication [10]. They have poor obstetric and fetal outcomes when 
compared with other viral hepatitis. 
Breastfeeding is not contraindicated. 
PREVENTION AND TREATMENT   
 Prevention is by proper hand washing and drinking safe water. Vaccines 
against HEV are in development. Two large placebo-controlled trials found 
that vaccination was more than 96 percent effective in preventing infection 
in high-risk settings. Pre- or Post-exposure immune globulin (IG) for 
prophylaxis of Hepatitis E infection is under trial.[11] 
HEPATITIS C 
Women chronically infected with hepatitis C virus (HCV) can have an 
uneventful pregnancy without worsening of liver disease or other adverse 
effects on the mother or fetus, though some studies have suggested potential 
harms. Transmission of the virus from mother to infant occurs but appears to 
be much less efficient than for hepatitis B, occurring in about 5 to 10 % of 
infants born to anti-HCV positive women. Antiviral treatment of pregnant 
women with hepatitis C or unusual precautions to reduce the risk of 
transmission (performing a cesarean delivery) are not recommended.  
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INTRAHEPATIC CHOLESTASIS OF PREGNANCY 
It is the most common condition peculiar to pregnancy, has a mild 
course in mother but an adverse effect on fetus. Geographical variation in 
incidence is wide, there is a seasonal variation peaking in November, 
have familial predisposition and tends to recur. (17) 
Etiopathogenesis: 
It is a multifactorial disease.  Exact etiology is not known.  Increased sex 
hormone synthesis and metabolism during pregnancy may be one of the 
factors. 
• Genetic factors may play a role. [12]Pauli Magnus et al 2006 
studied that “The ABCB4 (adenosine triphosphate-binding 
cassette, subfamily B, member 4) gene encoding the multidrug 
resistance 3 (MDR3) protein (a canalicular phospholipid 
translocator) is primarily involved in a subtype of progressive 
familial intrahepatic cholestasis called PFIC3. Heterozygous 
mutations in this gene have been found in women who had 
episodes of cholestasis during pregnancy. The prevalence of such 
ABCB4 gene mutations in Caucasian patients suffering from ICP 
is 16 percent.”[13] 
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• Role of estrogen & progesterone.[14] 
• Higher incidence in twin gestation favors ICP.[15] 
• Low s. selenium levels reduce the activity of some selenium 
dependent liver enzymes. 
Diagnosis: 
80% of cases usually occur in III trimesters of pregnancy.  
Generalized pruritus occurs after 30th week, relieved within 48 hours 
following delivery.  They have mild jaundice, 2-4 weeks after the onset of 
pruritus.  Nocturnal itching of trunk, palms and soles is severe along with 
insomnia and fatigue. 
Biochemical changes: 
There is rise in serum bile acids & mild elevation in S.transaminase 
and S.bilirubin level as shown in tabular column. 
Parameters Change 
S. bile acids 10-100 fold 
S. alkaline Phosphatase 7-10 fold 
S. bilirubin 2-5 
5’ nucleotidase 2 fold 
PT time N-2 fold 
Cholesterol 2-4 fold 
TG N-2 fold 
       Effects on mother are pruritus, PPH and gallstones. 
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FETAL OUTCOME 
Effects on fetus are prematurity, respiratory distress syndrome, meconium 
staining and fetal death. Williamson et al 2011states that 
“The incidence of prematurity varies greatly among studies (6 to 60 
percent), and may be related to the sudden development of a fetal 
arrhythmia  or vasospasm of the placental chorionic surface vessels 
induced by high levels of bile acids”.[16] Maternal serum bile acid 
concentration also  is a predictor of fetal outcome risk in cholestasis of 
pregnancy.[17] 
MANAGEMENT 
– Treatment is symptomatic and supportive. 
– Ursodeoxycholic acid 500mg BD or 300mg TDS relieves pruritus   
by increasing bile flow and and also improves the liver function 
tests. [18, 19] 
– Cholestyramine acts by reducing the ileal absorption of bile salts, so 
that their fecal excretion is increased. The dose of Cholestyramine is 
4gm four times a day.  
– Antihistamines can be given to relieve intense pruritus. 
– Frequent fetal monitoring by Non stress test. Delivery at 37 weeks 
as the risk of intra uterine death is more after 37 weeks.     
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ACUTE FATTY LIVER OF PREGNANCY 
Stander and Carden recognized AFLP in 1940 and this liver disorder is 
unique to human. It occurs in the third trimester and is more common with 
multiple gestations. 
CLINICAL MANIFESTATIONS 
Acute fatty liver occurs typically in the third trimester. The disease is 
always present before delivery, although not always diagnosed prior to 
delivery. 
The symptoms are nausea or vomiting (75 %),abdominal pain (particularly 
epigastric 50%), loss of appetite and jaundice. About 50% have signs of 
preeclampsia. [20]. 
PATHOGENESIS — The relation of AFLP with the inherited defects in 
mitochondrial beta-oxidation of fatty acids and long-chain 3-hydroxyacyl 
CoA dehydrogenase deficiency (LCHAD) had shown that some affected 
patients  and their fetus  have an inherited enzyme deficiency in beta-
oxidation. [21] These metabolites produced by the fetus or placenta are 
toxic to the liver resulting in liver disease. The role of LCHAD in the 
pathogenesis of acute fatty liver of pregnancy has been illustrated in many 
studies and is common in male fetus. 
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Swansea diagnostic criteria for  AFLP (Six or more features) 
• Vomiting 
• Abdominal pain 
• Polydipsia and polyuria 
• Elevated transaminases(3 to 10times) 
• Encephalopathy 
• High bilirubin (>14 µmol/L) 
• Hypoglycaemia (<4 mmol/L) 
• Elevated urate (>340 µmol/L 
• Renal impairment (creatinine>150 µmol/L) 
• Leucocytosis (>11×109/L) 
• Ascites or bright liver on ultrasound scan 
• Elevated ammonia (>47 µmol/L) 
• Coagulopathy (PT >14 sec or APTT >34 sec) 
• Liver biopsy showing micro vesicular steatosis 
DIAGNOSIS — AFLP is mostly diagnosed clinically and with laboratory 
and imaging results. 
Liver biopsy is diagnostic, showing the characteristic picture of the micro 
vesicular fatty infiltration of the hepatocytes. Because liver biopsy is 
invasive, it is not always performed. Liver biopsy should be approached 
with caution during pregnancy, and reserved for cases in which the 
diagnosis is in doubt. 
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Acute fatty liver of pregnancy 
 
High power view of an oil red O stain of a liver biopsy of acute fatty liver. 
There are vacuolated hepatocytes containing micro vesicular fat which 
stain red (arrows) Courtesy of Caroline ARiely, MD. 
TREATMENT AND COURSE — There is no specific medical treatment 
for AFLP.The primary treatment is prompt delivery of the fetus after 
maternal stabilization. 
Hypoglycemia is common and treated with a continuous infusion of 10 
percent dextrose solution. Coagulopathy is treated with fresh frozen 
plasma, packed red blood cells, cryoprecipitate and platelets. Severe cases 
require intensive care unit with mechanical ventilation. However, 
substantial morbidity and mortality can occur. [22] 
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HELLP SYNDROME  
HELLP syndrome is characterized by microangiopathic haemolytic 
anaemia, raised liver enzymes, and reduced platelet count. 
 Partial HELLP syndrome: Patients with one or two criteria of HELLP 
syndrome. 
INCIDENCE—The incidence of HELLP syndrome is 1 - 2 per 1000 
pregnancies and is seen in 15 to 20 percent of women with severe 
preeclampsia/eclampsia. Most of the patients are between 28 and 36 weeks 
of gestation. [23] 
Signs/symptoms 
Proteinuria                                     Right upper quadrant/epigastric pain 
Hypertension                                 Nausea, vomiting 
Headache                                       Visual changes 
Jaundice 
 Hypertension and proteinuria are seen in 85% patients. 
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DIAGNOSIS 
1. Microangiopathic haemolytic anemia with schistocytes (also known as 
helmet cells) on blood smears. Other features of hemolysis are raised  
indirect bilirubin and a low serum haptoglobin. 
2. Platelet count ≤ 1 lakh 
3. Total bilirubin ≥1.2 mg/dL 
4. Serum AST ≥70 IU/L 
Peripheral smear in microangiopathic haemolytic anemia showing 
presence of schistocytes. 
 
 
 
 
 
Peripheral smear with microangiopathic haemolytic anemia. Helmet cells 
(small black arrows), fragmented red cells (large black arrow), 
microspherocytes (blue arrows). The platelet number is reduced (red 
arrow) showing enhanced destruction. Courtesy of Carola von Kapff, SH 
(ASCP). 
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Differential diagnosis — Acute fatty liver of pregnancy, Gallbladder 
disease, Idiopathic thrombocytopenic purpura, Hemolytic-uremic 
syndrome and Thrombotic  thrombocytopenic purpura. 
Classificationof HELLP syndrome 
Mississippi system 
• Class I: platelets <50,000/mm3 
• Class II: platelets 50,000-1,00,000/mm3 
• Class III: platelets 100,000-1,50,000/mm3 
 AST>40 IU/L and LDH >600 IU/L 
 
Liver biopsy from a patient with HELLP syndrome. The zones 
immediately adjacent to the portal triads show collections of red blood 
cells, without inflammation or necrosis of hepatocytes. Courtesy of 
Caroline A Riely, MD. 
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MANAGEMENT 
 The cornerstone of therapy is delivery. Antihypertensives are used for 
treating severe hypertension. Magnesium sulfate is given intravenously to 
prevent convulsions. 
Pregnancies less than 34 weeks of gestation: There is no evidence that 
perinatal outcome is improved with expectant management when 
compared with fetus delivered after a course of glucocorticoids. There are 
no maternal benefits from expectant management. [24].  
Role of dexamethasone: Some recommend use of dexamethasone in 
patients with platelet counts less than 100,000.  Cochrane review of 11 
trials comparing corticosteroids with placebo in women with HELLP 
syndrome found no difference in maternal death, maternal morbidity, or 
perinatal death and concluded there was no clear evidence of benefit.[25] 
Complications 
DIC  21% 
Abruptio placentae 16% 
Acute renal failure 8 % 
Pulmonary edema 6% 
Subcapsular liver hematoma  1% 
Retinal detachment  1% 
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Fetal/neonatal long-term prognosis are most strongly associated with 
gestational age at delivery and birth weight. Prematurity is common (70 
percent), and may be complicated by intrauterine growth restriction and 
sequelae of abruptio placenta.[26] 
Biochemical differences between AFLP and HELLP 
  AFLP  HELLP 
Glucose 
 
low  
 
Normal 
Ammonia  High  Normal 
RBC   Normal  Hemolysis 
Platelet in   low to Normal  Low 
Fibrinogen  Low  Normal 
Prothrombin time  prolonged  Normal 
     
CHRONIC LIVER DISEASE AND PORTAL HYPERTENSION 
Pregnancy is unusual in women with severe chronic liver disease because 
of the associated anovulatory state. But women with less severe disease 
(chronic viral hepatitis) or those with non cirrhotic portal hypertension 
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(portal vein thrombosis) do not have diminished fertility and may become 
pregnant.[27] 
The increase in total blood volume associated with pregnancy may 
worsen pre-existing portal hypertension .The maternal complications of 
portal hypertension are variceal haemorrhage , encephalopathy,  hepatic 
failure, jaundice, malnutrition , and  the fetal complications are stillbirths 
and premature delivery. 
Esophageal variceal bleeding is more common during the second and 
third trimesters due to increased pressure of the expanding uterus on the 
inferior vena cava. Maternal mortality with acute variceal bleeds ranges 
from 20-50%.[27] 
Upper endoscopy should be performed in the second trimester for all 
pregnant women with portal hypertension. Patients at high risk for variceal 
hemorrhage should be considered for sclerotherapy. Prophylaxis with beta 
blockers, propranolol may be continued during pregnancy, but newborns 
should be monitored during the first days of life because of risks of 
hypoglycemia and bradycardia.[28] 
 Vaginal delivery is usually safe and early forceps delivery or vacuum 
extraction should be considered to prevent any rise in portal pressure due 
to prolonged straining during labour [29]. 
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Other chronic liver disorders are Wilsons disease, Budd-Chiari 
syndrome,  autoimmune hepatitis  (Primary Biliary Cirrhosis and Primary 
Sclerosing Cholangitis).  
GALLSTONES  
Gallstones are common in pregnancy due to increased cholesterol 
secretion, increased lithogenicity of the bile, and reduced gallbladder 
motility. 
By the third trimester10% of pregnant women have gallstones. 
Most gallstones regress in the postpartum period. 
The treatment may be conservative or surgical, depending on the 
severity of the symptoms. Laparoscopic cholecystectomy can be done for 
symptomatic gallstones in pregnancy.[30]Endoscopic retrograde 
cholangiopancreatography (ERCP) may be needed for 
choledocholithiasis. 
HEREDITARY SPHEROCYTOSIS 
Hereditary spherocytosis  is an autosomal dominant hematologic 
disorder. It also occur as an autosomal   recessive disorder with variable 
expression. 
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Clinical features Hemolytic anemia (of varying severity) with 
spherocytosis, intermittent jaundice, splenomegaly, and gall stones. 
 Diagnostic criteria 
 Red cell indices: Hb, MCV are decreased, MCHC, RDW, reticulocyte 
count are increased. Osmotic fragility  is increased. Blood smear shows  
spherocytes. Direct antiglobulin test   is negative.                                                    
Mild form of Hereditary spherocytosis do not have major 
problems. Hemolytic crisis is common during pregnancy. Few cases are 
diagnosed only during pregnancy. 
Symptomatic patients should undergo splenectomy to prevent 
hemolytic crisis in pregnancy [31] 
          HERPES SIMPLEX HEPATITIS IN PREGNANCY 
• Predominant in pregnant women. 
• Virus is herpes simplex type 2. 
• S.bilirubin is mildly elevated but S.transaminase is markedly 
elevated.  
• Maternal and fetal mortality is about 50%. 
• Acyclovir is the treatment of choice. 
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HYPEREMESIS GRAVIDARUM 
  The incidence of Hyperemesis in pregnancy is about 0.5 to 2 
percent.It is characterised by intractable nausea and vomiting and it is 
common in primigravida.It may cause in mild elevation of bilirubin and 
liver enzymes along with metabolic disturbances. Treatment is hydration 
and antiemetics. 
  According to Matsubra.S et al “In women with Jaundice in 
hyperemesis  gravidarum, ultrasound reveals biliary sludge and hydration 
concomitantly ameliorates the symptoms, jaundice and the biliary 
sludge”.[32] 
LEPTOSPIROSIS  
It is an infectious disease caused by spirochete leptospira 
icterohaemorhagiae. Rat is the natural host. Infected urine contains 
spirochetes which penetrates the skin or mucosa of humans. Initial phase 
begins with fever,headache and petechial rashes. Hepatitis, Acute tubular 
necrosis, meningitis complicates the second phase. The spirochaetes may 
cross the placenta and cause abortions in first and second trimester and 
also intra uterine death.[33] 
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MATERIALS AND METHODS 
 
STUDY PLACE: 
 Institute of Obstetrics and Gynaecology. 
STUDY GROUP: 
All cases of pregnancy with Jaundice in all trimesters admitted in Institute of 
Obstetrics and Gynaecology during the period 2011 – 2012. 
STUDY DURATION: 
. One year 2011-2012. 
TYPE OF STUDY: 
 A Prospective, observational  study. 
INCLUSION CRITERIA: 
 All Antenatal mothers with Jaundice in any trimester of pregnancy. 
EXCLUSION CRITERIA: 
• Associated comorbid condition like renal problem, Heart disease. 
• Known case of HbsAg positive patient not with Jaundice 
This prospective study of maternal and fetal outcome included 51 pregnant 
women with Jaundice admitted in Institute of Obstetrics and Gynaecology 
during the period 2011 – 2012. 
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 Elaborate history regarding Age, socio-economic status, obstetric history 
was obtained. Patients were enquired in detail about complaints and like  
nausea, vomiting, pruritus, anorexia, yellow  coloured urine, pale stools, 
edema legs, bleeding tendency, joint pain and  their duration. 
Past history of jaundice especially in previous pregnancy, history of 
blood transfusion, history of STI and history of jaundice in family members 
were noted. Much importance was given in taking note of the source of  
drinking water. 
Though general examination was done in all patients. Anaemia, 
jaundice, edema, bleeding gums, hepatic tremor were looked for 
Temperature, PR, B.P, CVS and RS  findings  were recorded. Abdominal 
examination was done to make out any liver and spleen enlargement and free 
fluid. 
Obstetric examination was done to note the size of uterus, lie, 
presentation and attitude of fetus, fetal heart rate, liquor volume and rough 
estimation of  fetal weight. Patients who were either in labour or seriously ill 
were admitted in  labour ward for intensive care. Patients with either good 
general condition or not in labour were admitted in antenatal ward for further 
evaluation. Provisional diagnosis was arrived. 
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Liver function tests like S.Bilrubin total, direct and indirect, total 
proteins, albumin and globulin, SGOT, SGPT, S.Alkaline phospatase, 
clotting time, , bleeding time and USG were done. Complete hemogram and 
reticulocyte count were done. Coagulation profile was done for all and 
values were noted. 
Viral markers study including HBs Ag, Anti HAV IgM, Anti HCV 
Ab, Anti HEV IgM by enzyme immuno assay (ELISA) technique was done. 
VDRL and HIV examination was done in all patients. Medical 
gastroenterologist opinion was obtained in  nearly all cases. 
Dark field microscope examination was done for leptospirosis. Blood 
samples were also sent for MSAT. Antibiotics were started as soon as dark 
field microscope results were obtained. 
Labour was closely monitored with partogram. Mode of delivery was 
recorded. Jaundice per se was not an indication for caesarean section. 
Vaginal delivery with close monitoring was preferred and caesarean section 
was done only for obstetric indication. Blood grouping and typing was done. 
After cross matching fresh blood and FFP was kept ready as alternation in 
coagulation profile was expected in jaundice complicating pregnancy. 
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Soon after delivery all babies were assessed by paediatrician. Alive or 
dead, sex of the body, gestational age at birth, weight, Apgar score and 
presence or absence of any congenital anomalies were looked for and noted. 
As per paediatrician opinion sick babies were admitted in preterm 
ward for intensive care. Babies were followed by and cause of death was 
noted. 
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OBSERVATION 
 A prospective study of all the antenatal patients admitted with 
jaundice in pregnancy at the Institute of Obstetrics and Gynaecology 
Chennai during 2011-2012 was undertaken. 
 Total number of antenatal admissons during this period was 
17,890. Total number of patients with jaundice was 51 and they are the 
present study group. 
1. INCIDENCE OF JAUNDICE COMPLICATING 
PREGNANCY 
 The incidence of jaundice complicating pregnancy during this 
period in our Hospital is 0.29%.  
TABLE - 1 
Year 
Total 
antenatal 
admissions 
No of 
Jaundiced 
 pregnant 
women 
Percentage 
Incidence per 
1000 
population per 
year 
2011-12 
 
17890 
 
51 0.28 2.85 
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S.No Age group in years
1 15
2 20
3 25
4 30
5 35
 Total
 
 The patients in the study group were in the age range from 18 years 
to 36 years. Nearly 74% of the jaundiced patients were between 20 and 29 
years. 
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9.8
31.37
43.13
13.72
1.96
Age Group in Years
AGE INCIDENCE
-19 20-24 25-29 30-34 35-40
AGE INCIDENCE 
 
TABLE -2 
 
 No of Cases 
-19 5 
-24 16 
-29 22 
-34 7 
-40 1 
 51 
 
 
 
Percentage 
9.8 
31.37 
43.13 
13.72 
1.92 
100 
  
45.09%
DISTRIBUTION AS PER SOCIO
S.E Class 
III 
IV 
V 
 
 
 The incidence of Jaundice is more common in low socio
groups. About 92.1 of cases belonged to class IV 
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7.84%
47.05%
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TABLE – 3 
 
Number of cases Percentage
4 7.84
24 47.05
23 45.09
and V. 
 
III
IV
V
 
 
 
 
 
-economic  
 
  
0
10
20
30
40
50
60
Primi 
Gravida
Pe
rc
en
ta
ge
INCIDENCE IN RELATION TO 
INCIDENCE IN RELATION TO GRAVIDITY
S.No. Gravidity
1 Primigravida
2 Second 
3 Third 
4 Fourth 
5 Fifth 
 
Maximum number of cases 
were 35.29 %. 
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Gravida
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Gravida
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TABLE -4 
 
 No.of Cases 
 28 
gravida  18 
gravida 3 
gravida 1 
gravida 1 
were primigravida 54.9%
 
 
 
Percentage 
54.9 
35.29 
5.88 
1.96 
1.96 
,second gravida 
  
I Trimester
II Trimester
III Trimester
INCIDENCE IN RELATION TO 
INCIDENCE IN RELATION TO GESTATIONAL AGE
S.No Period of 
Gestation
1 I Trimester
2 II Trimester
3 III Trimester
 
 Out of 51 cases, 41 cases (80.39%) presented with Jaundice during 
III trimester. 
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TABLE -5 
 
 
No.of Cases Percentage
 2 
 8 
 41 
 
 
100
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ANALYSIS OF PAST HISTORY
ANALYSIS OF PAST MEDICAL 
S.No. Past History
1 Contact with jaundice
2 Jaundice in previous 
pregnancies 
3 Previous history of jaundice
4 Hep B immunization
5 H/o  Blood transfusion
 
 3 Patients had 
history of blood transfusion among which one was HBsAg positive
Hepatitis B immunization.
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Jaundice in 
previous 
pregnancies 
Previous 
history of 
jaundice
Hep B 
immunisation
H/o  Blood 
transfusion
1.96
5.88
19.6
 
HISTORY
TABLE-6 
 No.of Cases 
 3 
 
1 
 3 
 10 
 2 
history of contact with jaundice. 2 patients had 
 
 
3.92
 
Percentage 
5.88 
1.96 
5.88 
90.6 
3.92 
.10 had 
  
7
SOURCE OF WATER
SOURCE OF DRINKING WATER
Water 
Safe 
Unsafe 
 
 5% of patients were utilising safe water for drinking purpose and 95% 
patients were ignorant about safe water.
  
 
 
 
 
 
 
 
 
 
 
53 
13.72
44
86.27
 
TABLE – 7 
Number of cases Percentage
7 13.72
44 86.27
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ANALYSIS OF THE PRESENTING 
ANALYSIS OF THE PRESENTING SYMPTOMS
S.No Symptoms
1 High coloured Urine
2 History of fever
3 Loss of appetite
4 Nausea and vomiting
5 Upper abdominal pain
6 Itching 
7 Clay stools
8 Abdominal distension
 
 On analysing the presenting symptoms 86.27% had high color urine. 
Nausea and vomiting were present
fever, loss of appetite and upper abdominal pain. The number of cases with 
percentage of various symptoms are sho
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39.21 45.09
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35.29
5.88 5.88
SYMPTOMS
TABLE -8 
 No.of Cases 
 44 
 20 
 23 
 36 
 18 
3 
 3 
 7 
 in 70.6%.Other predominant symptoms were 
wn in Table-8. 
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ANALYSIS OF CLINICAL SIGNS
ANALYSIS OF CLINICAL SIGNS
S.No Clinical Signs
1 Jaundice
2 Hepatomegaly
3 Splenomegaly
4 Scratch marks
5 Ascites 
 
 Jaundice was present in all the 
 Splenomegaly, Scratch marks and Ascites.
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TABLE-9 
 
 
 
 
 No.of Cases 
 51 
 9 
 4 
 3 
4 
cases.Other signs were Hepatomegaly,
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DURATION OF COMPLAINTS
DURATION OF COMPLAINTS
Duration of 
Complaints 
1-5 days 
5-10 days 
11-15 days 
 
 45.1 % of patients had the complaints for 1
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TABLE- 10 
 
Number of cases Percentage
23 45.1
20 39.2
8 15.6
-5 days. 
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RESULTS OF URINE ANALYSIS
Tests 
Bile pigments 
Bile salts 
Protein 
 
 92.15% of patients showed positive for Bile pigments and  Bile salts in 
the urine. 19.6% patients were positive for Protein.
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ANALYSIS OF URINE
 
 
 
TABLE-11 
 
Present Percentage
47 
47 
7 
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SERUM BILIRUBIN LEVEL
SERUM BILIRUBIN LEVEL
S.No 
1 
2 
3 
4 
 
 The level of S.Bilirubin varied widely between 2.8 to 18.4 mg / dl. 7.84% 
of patients had high S.Bilirubin more than 16 mg / dl.
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TABLE -12 
 
Serum Bilirubin 
(mg%) 
No.of Cases 
2-5 16 
6-10 21 
11-15 10 
16-20 4 
 
 
 
 
 
 
Percentage 
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7.84 
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SERUM TRANSAMINASE LEVEL
S.No 
1 
2 
3 
4 
5 
6 
 
 The serum transaminase level was below
About  5.88% patients had level more than 500 IU/L. 
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31.37
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7.84
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SERUM SGPT LEVEL
 
 
TABLE-13 
 
SGPT No.of Cases 
<100 7 
100-200 16 
200-300 13 
300-400 8 
400-500 4 
>500 3 
 100 IU/L in 13.72% of patients.
 
 
 
 
 
Percentage 
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31.37 
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15.68 
7.84 
5.88 
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Alkaline Phosphat
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Upto 200 
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 S.Alkaline phosphatase was more than 400 U/L in 21.
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TABLE-14 
 
ase No.of Cases 
19 37.25
21 41.17
7 13.72
2 
2 
5% .
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DISTRIBUTION OF CASES ACCORDING TO ETIOLOGY 
 
TABLE – 15 
S.No Diagnosis No.of 
Cases 
Percentage Incidence per 
1000 Population 
1 Viral Hepatitis 26 50.98 1.4 
2 HELLP Syndrome 7 13.72 0.3 
3 Intrahepatic cholestasis of 
pregnacy 
3 5.88 0.16 
4 Acute Fatty liver of 
pregnacy 
4 7.84 0.22 
5 Chronic Liver Disease and 
Portal Hypertension 
4 7.84 0.22 
6 Blood Reaction 1 1.96 0.05 
7 Leptospirosis 2 3.92 0.11 
8 Hyperemesis Gravidarum 1 1.96 0.05 
9 Hemolytic jaundice 
(Hereditary Spherocytosis) 
1 1.96 0.05 
10 Undetected 2 3.92 0.11 
 
 Viral hepatitis was the commonest etiology in 50.98%.Of this, 
Hepatitis E detected in 14 cases, Hepatitis B detected  in 10 cases. HELLP 
Syndrome was the next common etiology in 30.72%.Acute Fatty liver of 
pregnancy and Chronic Liver Disease with Portal Hypertension were the 
cause in 7.84%. Hemolytic jaundice due to Hereditary Spherocytosis was 
seen in one patient. The cause was Undetected in 2 cases.  
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4
1 2 1 1
7.84 7.84
1.96
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1.96 1.96
Chronic Liver 
Disease 
Blood Reaction Leptospirosis Hyperemesis 
Gravidarum
Hereditary 
Spherocytosis
 
2
3.92
Undetected
No.of Cases
Percentage
  
58.82
3.92
MODE OF DELIVERY
Mode 
Labour Natural 
Assisted breech delivery
Outlet forceps with 
episiotomy 
Abortion 
LSCS 
 
 
 Out of 51 patients, 
in I trimester got discharged after
 patients delivered vaginally. 21.56% patients had LSCS. 
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MODE OF DELIVERY 
 
TABLE -16 
Number of cases Percentage
30 58.82
 
2 3.92
1 1.96
1 1.96
11 21.56
45 delivered. 4 patients who were in II trimester and 1 
 treatment. 1 patients died antenatally. 70% 
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PREGNANCY OUTCOME
PREGNANCY OUTCOME
S.No Pregnancy 
outcome
1 Abortion
2 Preterm delivery
3 Term delivery
 
Total 
 
 Out of 45 patients 23 had Term delivery
Preterm delivery ,one had abortion.
 
 
 
 
 
 
 
 
MATERNAL OUTCOME 
1 Total number of antenatal admissions
2 Total number of maternal mortality
3 Incidence of maternal  mortality
4 Total number of jaundiced cases
5 Total number of mortality due to jaundice
6 % of mortality in jaundice
7 % of mortality due to jaundice in relation to total
maternal mortality 
64 
Preterm 
delivery
Term delivery
21 23
46.6
51.1
Percentage
No.of Cases
 
TABLE -17 
 
 
No.of Cases Percentage
 1 
 21 
 23           
45 
, 21 patients had  
 
(2011-2012) 
Table - 18 
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TYPE OF COMLICATIONS
Complications
DIVC 
Abruption 
Atonic PPH 
Hepatic 
encephalopathy 
Hepatorenal failure
Oesophageal varices
Total 
 
 In four patients Hepatic encephalopathy was seen
in 5 patients. DIVC was seen in 3 patients.
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TABLE -19 
 Number of cases Percentage
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MATERNAL MORTALITY
No of Maternal Death
 
 
CAUSE
S.No 
 
Diagnosis
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HELLP 
Syndrome 
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Portal 
hypertension 
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Acute Fatty liver 
of pregnancy 
 
 
Among 4 deaths two were due to Acute fatty liver of Pregnancy, one died of 
HELLP and one due to rupture of Esophageal
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S OF MATERNAL MORTALITY 
TABLE - 20 
 No.of cases 
 
Maternal 
Mortality 
 
7 
 
1 
 
4 
 
1 
 
4 
 
2 
 
 varices. 
Percentage 
 
25 
 
25 
 
50 
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RELATION OF SERUM BILIRUBIN TO MATERNAL MORTALITY 
 
TABLE-21 
S.No Serum 
Bilirubin level 
(mg%) 
No of 
Patients 
Maternal 
Mortality 
Percentage of 
Maternal 
Mortality 
1 2-5 16 1 25 
2 6-10 21 1 25 
3 11-15 10 2 50 
 
Total 51 4 100 
 
 Among 4 cases two had S.bilirubin more than 10 gm/dl. 
 
 
RELATION OF SERUM TRANSAMINASE LEVEL TO MATERNAL 
MORTALITY 
TABLE – 22 
S.No SGPT No.of Cases Maternal 
Mortality 
Percentage of 
Maternal 
Mortality   
1 <100 7 0              0 
2 100-200 16 1 25 
3 200-300 13 1 25 
4 300-400 8 1 25 
5 400-500 4 1 25 
6 >500 3 0             0 
 
Serum transaminase level  had no  relation to maternal mortality. 
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Outcome
Term live babies 
Term IUD babies 
Preterm live babies 
Preterm still Birth / IUD
Born alive & dead (all 
preterm) 
Perinatal mortality
 
 Perinatal mortality was 35.5% of these 80% was due to prematurity. 
There were 37 live birth .Of these 16
preterm babies born alive,died during neonatal period.
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Percentage
Number of cases
FETAL OUTCOME 
 
TABLE – 24 
 Number of cases 
21 
2 
12 
 10 
4 
 
16 
 were preterm. 21 were Term 
 
Percentage 
46.6 
4.44 
26.6 
22.2 
8.8 
35.5 
 
babies.4  
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FETAL OUTCOME AND ETIOLOGY
 
CORRELATION OF PERINATAL MORTALITY WITH ETIOLOGY
Etiology 
HELLP 
Hepatitis B 
Hepatitis E 
Chronic Liver 
Disease 
AFLP 
Leptospirosis 
OCP 
Total 
 
Poor fetal outcome was seen with HELLP syndrome 31.25%, Hepatitis E 25
Hepatitis B 12.5%, and intrahepatic cholestasis 
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12.5
25
6.25 6.25
TABLE - 25 
No of perinatal 
deaths 
5 31.25
2 12.5
4 
1 6.25
1 6.25
1 6.25
2 12.5
16 100
12.5%.  
6.25
12.5
. 
% 
 
 
25 
 
 
 
 
 
%, 
  
BABY WEIGHT AND NEONATAL DEATH
INFLUENCE OF BABY WEIGHT ON FETAL OUTCOME
S.No Baby weight 
(kg)
1 <1.5
2 1.5-2.5
3 2.5-3.5
4 >3.5
 
          24 babies were below 2.5 kg and among them
 Most of them were preterm.
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57%25%
18%
0%
<1.5 1.5-2.5 2.5-3.5 >3.5
 
TABLE -26 
 
 
No of 
babies 
Neonatal 
death 
Percentage of 
Neonatal death
 11 9 
 13 4 
 20 3 
 1 0 
, there was 80% mortality.
 
 
 
 
56.25 
25 
18 
0 
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DISCUSSION 
INCIDENCE:  The incidence of jaundice in pregnant women at 
institute of obstetrics and Gynaecology (IOG) Chennai during 2011-2012 
(1 year) was 0.28%. i.e. 2.85 per 1000  population. In India the incidence is 
between 0.1 to 0.4%. 
           The incidence quoted in studies from various places: 
Sarkar et at (Calicut) 1992                  0.23% 
Reddi Rani et at (Pondicherry) 1993   0.11% 
DevinderKaur et at (Delhi) 2001       0.09% 
Institute of obstetrics and Gynaecology 2002    0.14% 
The reason for varied incidence may be due to many patients with mild 
icterus not seeking medical attention. 
AGE: In our study, 31.3% patients were in the age group of 20-24 years. 
43.13% patients were in the age group 25-29 years which showed the 
increase in the mean age of marriage nowadays. 
SOCIO ECONOMIC STATUS: 92% of our study group belonged to 
lower socio economic class and 86% were consuming unsafe water. 
Hepatitis E and Hepatitis A are more prevalent in lower socio economic 
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class due to unsafe drinking water, lack of sanitation and poor personal 
hygiene. 
 Nargis Begum et al 2009 studied about the seroprevalence (IgG 
Anti HEV) of subclinical HEV infection in pregnant women and reported 
that exposure to Hepatitis E was more in lower socio economic class.[34] 
GRAVIDITY AND GESTATIONAL AGE 
 Primigravida and second gravida were common (90%) in our study 
group.Among them 55% were Primigravide. 
          80% of our patients were in III trimester. Harshad et al 2008, 
Shukla et al 2011 and other studies have stated that maximum incidence of 
jaundice was in III trimester and morbidity and mortality were also higher 
during III trimester. 
PAST HISTORY:   
In this study 3 patients had contact with Jaundice. Two had history of 
blood transfusion and among them 1 had Hepatitis B infection. Among the 
3 patients diagnosed as intra hepatic cholestasis of pregnancy, one had 
history of jaundice in her mother during her antenatal period and one 
patient had twin pregnancy. 
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SYMPTOMS AND SIGNS 
All patients were icteric (100%). Nausea and vomiting in 70.5% cases, 
loss of appetite in 45% cases, Fever in 39%  cases, upper abdominal pain 
in 35% cases were the other predominant symptoms. Hepatomegaly was 
found in 9 patients. Splenomegaly was found in 4 patients who had chronic 
liver disease and 4 patients had ascites. 
ETIOLOGY 
Viral Hepatitis was the etiology in 51% of cases, HELLP syndrome in 
13.72% patients, Acute fatty liver of pregnancy in 7.8% patients chronic 
liver disease in 5.9% patients intra hepatic cholestasis in 5.9% patients. 
Other uncommon causes were Leptospirosis in 3.92%, Blood reaction in 
1.96%, Hyperemesis in 1.96%, Hemolytic  Jaundice in 1.96% The cause 
for Jaundice was undetected in 2 cases. 
VIRAL HEPATITIS: Viral Hepatitis was the cause in 51% cases 
comparable to the study by Shukla et al 2011 who reported  57% and 
Harshad et al 2008   reported 47% cases of viral hepatitis.[35,36] 
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       Prevalance of Viral Hepatitis in Pregnant Women. 
 
Hepatitis A - Patra et al  2005  Delhi    0.5% 
    Beniwal et al 2005 Delhi  5.2% 
Hepatits B. - Harshad et al 2008 Bangalore 16% 
    Rathi  et al 2007 Mumbai  5%  
  Shukla et al 2011 Delhi  37% 
Hepatits E. - Harshad et al 2008 Bangalore 31% 
    Rathi  et al 2007 Mumbai  14% 
    Shukla et al  2011 Delhi  18% 
Hepatits C. - Shukla et al 2011  Delhi  4% 
    Beniwal  et at  2005 Delhi 0% 
In this present study, Hepatitis E was diagnosed in 23% cases, Hepatitis B   
in 21% cases and Hepatitis A in 5.8% cases. 
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HELLP SYNDROME: 13.72% of cases had HELLP Syndrome in our 
study. Rathi.U et al 2007 reported 52.3% of cases with liver dysfunction 
due to preeclampsia and HELLP.[37] 
CHRONIC LIVER DISEASE : 4 cases had chronic liver disease. Among 
them, 3 had non-cirrhotic portal hypertension (NCPH). Agarwal et al 2001 
studied 50 pregnant patients with NCPH and reported that in 56 % patients. 
NCPH was detected  first during pregnancy. In India Portal hypertension is 
commonly due to Non cirrhotic portal fibrosis and extra hepatic portal vein 
obstruction (EHPVO). But in western countries Portal hypertension is 
mostly due to cirrhosis.[38] 
ACUTE FATTY LIVER OF PREGNANCY: AFLP was diagnosed in 4 
cases with the clinical features and biochemical parameters. All of them 
had more than 6 features of Swansea criteria for AFLP. 
INTRA HEPATIC CHOLESTASIS:  Intra hepatic cholestasis of 
pregnancy was diagnosed in 3 patients, one had history of jaundice in her 
mother during her antenatal period and one patient had twin pregnancy. 
HEREDITARY SPHEROCYTOSIS: We had one case of hemolytic 
jaundice due to hereditary spherocytosis. Pajor et al 1993 studied 19 
pregnancies with hereditary spherocytosis, concluded that pregnancy 
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precipitated hemolytic anaemia and maternal and fetal outcome was 
favourable after splenectomy.[31] 
OTHERS: Leptospirosis was diagnosed in 2 cases by MSAT.  Shalini et 
al (2009) reported a case of leptospirosis with Jaundice, coagulopathy and 
intra uterine death.[33] 
          One was due to Hyperemesis gravidarum. Matsubara’s et al 
reported that Jaundice in Hyperemesis is due to biliary sludge and it is 
relieved by hydration.[32,41] 
BIOCHEMICAL PARAMETERS 
  In our study, SGPT and SGOT levels more than 500 IU/ml were 
associated with viral hepatitis. Harshad et al 2008 also reported that  
marked elevation of bilirubin and transaminases (10 fold) occured in viral 
hepatitis whereas patients with pregnancy associated liver disease like 
HELLP, Intrahepatic cholestasis and Hyperemesis had  only 2-3 fold 
elevation.[36] 
MANAGEMENT  
      Patients with Mild Jaundice were managed with supportive measures 
like Bed rest, Intravenous Dextrose, High carbohydrate diet, Vitamin K 
and Syrup Lactulose. Ursodeoxycholic acid tablets 500 mg BD was given 
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to patients with pruritus. Severe cases required intensive care management.   
22 patients were transfused blood and  27  patients were transfused fresh 
frozen plasma. Obstetric interventions were done for HELLP and AFLP. 
All patients were monitored with serial Liver function tests and 
coagulation profile until recovery. 
PREGNANCY OUTCOME: Among the 57 patients 5 patients were 
recovered and discharged. One patient died antenatally. 23patients had 
term delivery, 21 had preterm delivery and 1 patient had therapeutic 
abortion due to hemolytic crisis in hereditary spherocytosis. 
MATERNAL OUTCOME: 
 In the present study 7.8% patients died, 35 % patients developed 
complications and 58% had uneventful recovery. 
Complications: 9.8% patients had atonic PPH. 5.8% had DIVC, 7.8% 
had Hepatic encephalopathy. Abruption, Hepatorenal failure, Esophageal 
varies was seen in 3.9 % each.  
         The patients with atonic PPH, DIVC, and Abruption were treated 
with blood, fresh frozen plasma and platelets. 2 patients with renal failure 
recovered with multiple sittings of dialysis. 
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 Jain.S et al 2000 reported 52 patients with fulminant hepatic failure 
and concluded that renal dysfunction was the indicator of poor prognosis in 
patients with fulminant hepatic failure.[39] 
CAUSES OF MATERNAL MORTALITY 
 Among 4 deaths two were due to Acute fatty liver of Pregnancy, 
one died of HELLP and one due to rupture of Esophageal varices. 
AFLP: The two patients were primigravida and in III trimester. Both had 
vomiting, abdominal pain, High bilirubin, High transaminases, 
Coagulopathy (raised prothrombin time) and Encephalopathy. 
          Apart from the above findings one patient had leucocytosis, 
Hypoglycemia, bright liver on USG and the other had ascites and renal 
impairment.  One had intrauterine death and other had a live baby , and 
both delivered by normal vaginal delivery. Their condition deteriorated 
soon after delivery, developed Grade III encephalopathy was on ventilatory 
support but could not be revived. 
Rathi .U et al 2007 reported 3 cases of AFLP and among them 2 cases 
died of DIVC and multiorgan failure.[37] 
 Third patient died of HELLP syndrome, had severe hypertension, 
proteinuria, ascites delivered a dead born baby, died of DIVC and 
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Hepatorenal failure.Rathi.U et al 2007 reported 25% mortality due to 
Preeclampsia associated liver dysfunction. 
       The fourth patient was a case of Non-cirrhotic portal hypertension 
with grade III Esophageal varices died due to massive hematemesis during 
second trimester. She was an unbooked case.  
         Study by Peitsidou et al 2007 showed that risk of variceal bleeding 
increased to 62-78% if endoscopy revealed esophageal varies and should 
be treated by sclerotherapy or variceal ligation. Agarwal et al (1999) 
reported that esophageal varices was the most feared complication of portal 
hypertension. West brook et al (2011) reported one death in pregnancy due 
to variceal bleeding.[40] 
        Mortality due to viral hepatitis was not seen in the present study 
though many patients of hepatitis E had severe morbidity. Study by 
Jayanthi&Udayakumar et al 2008, Chennai[42]observed that mortality 
rate of Hepatitis E infection in southern India was very low 3-4% 
compared to high mortality 30-100% seen in studies from Northern India. 
Study by Harshad et al 2008, Bangalore reported that mortality was 41% 
in pregnancy associated liver disease and 7.5% in viral hepatitis and 
concluded due to Hepatitis E was low. 
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FETAL OUTCOME             
In the present study among 45 live births, 33 (73.4%) were live births 
12(26.6%) were intra uterine deaths. Preterm deliveries were 48.8% 
(26.6% live birth and 22.2% intra uterine deaths).  
The higher incidence of preterm delivery supported by Veronica et al 
(2006) 56%, Kumar et al (2003) 66.6% and Harshad et al (2008) 32% 
is due to high fever,  increased cytokine release, disturbed hormonal 
status and debilitating effects of viremia of hepatitis. 
The perinatal mortality in our study was 35.5% comparable to Rathi.U 
et al 2007 who reported 35.4% and Kumar et al reported 26.5%.[43] 
Among 16 Perinatal deaths, HELLP syndrome constituted 31.2%, 
Hepatitis E 25%, Hepatitis B 12.5%, and intrahepatic cholestasis 
12.5%. According to Williamson et al 2011, the poor fetal outcome in 
intrahepatic cholestasis of pregnancy was due to the toxic bile acid 
level in the fetus causing fetal arrhythmia. 
One intrauterine death was seen with chronic liver disease. Westbrook 
et al 2011 reported 26% of fetal loss with chronic liver disease.53.3% 
babies were below 2.5 kg in our study and among them there was 80% 
mortality. Shukla et al 2011 reported 30.8% low birth weight babies. 
 81 
 
SUMMARY 
1. The study was done in Institute of Obstetrics and Gynaecology, 
Egmore Chennai for one year(2011-2012) 
2. The study was done with an aim to diagnose the cause, to assess 
the maternal and fetal outcome and to analyse the preventive 
measures. 
3. Total antenatal admissions during the study period was 17890 of 
which 51 patients had jaundice and the incidence was 0.29%. 
4. Major portion of study population belonged to the age group 20-30 
years and constituted about 75%. 
5. Incidence of jaundice was highest among primigravida (52%). 
6. About 92% patients belonged to lower socioeconomic class and 
86% were consuming unsafe water. 
7. The maximum incidence of jaundice was in 3rd trimester and the 
complications were also high during that period. 
8. Most of the patients 86% had yellowish discoloration of urine. The 
other predominant symptoms were nausea and vomiting, fever, loss 
of appetite and abdominal pain. 
9. All the patients were jaundiced 100%. Splenomegaly was detected 
in patients of chronic liver disease (CLD) and ascites found in both 
HELLP syndrome and CLD patients. 
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10. Bile salts and bile pigments were positive in the urine of 92% 
patients  
11. High level of S.Bilirubin and S.Transaminase levels were noticed 
in viral hepatitis. 
12. Complication were severe in 18% patients(35%). 
13. Viral hepatitis was the commonest etiology in 51% patients, the 
next was HELLP syndrome in 13.7% 
14. 3 cases of intrahepatic cholestasis of pregnancy was diagnosed 
among which one had twin pregnancy and one had history of 
jaundice in her mother during her antenatal period. 
15. Maternal mortality rate was 7.8% .Among 4 patients who died, 2 
had acute fatty liver of pregnancy, one had HELLP syndrome and 
one had Non-Cirrhotic portal hypertension. 
16. Normal vaginal delivery occurred in 58% patients and 21% 
patients had LSCS. 
17. Blood was transfused in 22 patients, FFP in27 patients. 
18. Preterm delivery was high in our study constituting 46% and the 
term delivery was 51% . 
19. The preterm intrauterine death was 22.2% and term intrauterine 
death was 4.44%. 
20. Among the 2 term intrauterine death one due to hepatitis B and one 
due to hepatitis E. 
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21. The neonatal mortality was 35% and among them 90% was 
preterm. 
22. HELLP syndrome and hepatitis E were the major cause for poor 
fetal outcome. 
23. About 55% babies weighed less than 2.5 kg and mortality was 80% 
among them. 
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CONCLUSION 
Although  liver dysfunction is infrequently seen in pregnancy, it can 
result in severe maternal and fetal compromise. 
    Failure to the screen for Hepatitis B can result in a newborn that will be 
a hepatitis carrier for life. Hence, obstetrician must remain vigilant. 
   Jaundice co-existent with pregnancy is a burning problem in 21st 
century. 
   By evaluating various socio-economic factor, etiological factors, 
maternal and fetal outcome following points arrived. 
 All antenatal  cases should be booked. 
 All pregnant patients should be screened for Hepatitis B. 
 Safe drinking water should be provided for all. 
 Proper sanitation facilities and sewage disposal should be made 
available to all. 
 Women health education to be made compulsory. 
 Improved sanitary precautions should be taught during antenatal 
visits. 
 Hazards of promiscuity to be explained. 
 Health workers should be trained in diagnosing jaundice early and 
should refer to higher centres. 
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 Health education regarding all the above should be given to 
pregnant patients at the time of first booking. 
 All cases of Jaundice complicating pregnancy should be delivered 
in tertiary centres where facilities for blood and blood products are 
available. 
 Leptospirosis also to be kept in mind. 
 Detection and correction of coagulation failure earlier reduces 
mortality. 
 Babies of Hepatitis B surface Ag positive mothers should be 
immunised against Hepatitis B. 
 Good NICU is must to manage the preterm babies. 
 Awareness about jaundice and its complications should reach every 
obstetrician. 
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INSTITUTE OF OBSTERICS AND GYNAECOLOGY 
EGMORE – CHENNAI 
 
DISSERTATION – JAUNDICE IN PREGNANCY  
 
Serial No : 
Name   :    Age  :  IP No : 
Address  :    Occupation :  Income: 
Socioeconomic Status   
I II III IV V 
     
 
Booked Un Booked 
  
        Religion  : 
 
 
Gravida :  
 
  
LMP : 
EDD : 
D.O.A  :      Time : 
D.O.Delivery :      Time : 
D.O. Discharge:       Time : 
A.M.A/ Death :      Time : 
Gestational Age at Admission : 
 
I tri II tri III tri Labour  
    
 
 
Obstetric Table : 
G P L A 
    
 
 
  
Primi Multi 
 1 2 3 4 >4 
     
  
 
Complaints: 
€ Nausea, vomiting 
€ Malaise, Pruritus 
€ Anorexia 
€ Yellow colored urine 
€ Pale stool 
€ Swelling of legs 
€ Joint Pain 
€ Bleeding tendency 
€ Others  
 
 
Past History : 
€ H/O Jaundice in previous pregnancy 
€ H/O blood transfusion 
€ H/O Contact with jaundiced Pt 
€ H/O Any surgery 
€ H/O Hepatitis immunization  
 
Marital History : 
 
 
Personal History : 
 
 
Dietary Habit : 
 
 
Source of Drinking Water : 
 
 
General Examination : 
 
€ Fever 
€ Anaemia, Cyanosis 
€ Icterus   
€ Pedal edema 
€ Hepatic tremor  
€ Petechia Hmge 
€ Free fluid 
 
 
Eyes Tongue Palms Soles Palate  
     
  
 
 
Vital Data : 
€ PR  : 
€ BP  : 
€ CVS : 
€ RS  : 
€ CNS : 
P/A Liver : 
   Spleen 
   Uterus : Size 
   Fetus 
Single Multiple 
  
   
   FH :  
Present Absent 
  
   Presenting Part : 
Investigations :      Viral Markers: 
ℵ Urine Albumin      
ℵ Urine Sugar       
ℵ Blood Hb% 
ℵ Blood Urea 
ℵ Blood Sugar 
ℵ S.Creatinine 
ℵ S.Bilirubin T 
ℵ S.Bilirubin D 
ℵ S.Bilirubin I 
ℵ T.Proteins 
ℵ Albumin  
ℵ Globulin 
ℵ S.Uric acid 
ℵ SGOT 
ℵ SGPT 
ℵ S.Alkaline Phosphatase 
ℵ Complete Hemogram 
ℵ USG 
ℵ CT, CRT, B.T. 
Diagnosis -  Provisional :    Final  : 
 
Management : 
 
 Supportive Rx  / Antiviral drugs.  
 
  
 
€ IgM anti HAV 
€ HB (s) Ag 
€ IgM anti HBC 
€ Anti HCV Ab 
€ IgM anti HEV 
  
 
 
Labour :  
Spont Induced 
  
 Onset of labour 
 Time of Onset of labour / induction 
 Time of rupture of membranes 
 Duration of I stage 
 Duration of II stage 
 
Mode of delivery : 
 
Vaginal Instrumental Caesarean 
LN LN with epi Forceps Vacuum Emergency Elective 
 
Prophylactic Methergin / Oxytocin 
Amount of blood Loss 
Management of PPH – Blood transfusion :    surgery: 
Maternal Outcome : 
Morbidity    - infection / PPH 
Mortality     -  
Complete recovery  - Duration from admission 
Admission    - Delivery interval 
Delivery    - Discharge / Death interval 
 
Fetal Outcome : 
 
 1. 
 
 2. Sex  
 3. 
 
 4. Weight   
 5. Apgar 1’ 
                5’ 
6. Any congenital anomalies / Neonatal Jaundice 
 
7. If Born alive dead – cause of death . 
 
  
Normal Excessive 
  
Alive Dead Still Birth BAD 
    
Male Female 
  
Pre Term Term Postmature 
   
<1.5kg 1.5-2.5kg 2.5-3.5kg >3.5kg 
    
  
 
PATIENT CONSENT FORM 
STUDY TITLE: A PROSPECTIVE STUDY ON MATERNAL & FETAL 
OUTCOME IN JAUNDICE COMPLICATING 
PREGNANCY STUDY CENTRE:   
 Institute of Obstetrics and Gynaecology, Egmore, Chennai. 
PARTCIPANT NAME:  AGE:   I.D.NO: 
 I confirm that I have understood the purpose of the above study. I have the 
opportunity to ask the question and all my questions and doubts have been answered to my 
complete satisfaction. 
  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving any reason, without my legal rights being affected. 
 I understand that investigator, the institution, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in respect to the 
current study and further research that may be conducted in relation to it, even if I withdraw 
from the study. I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from the study. 
 I hereby consent to, undergo complete physical examination, and diagnostic tests 
including hematological, and ultrasonogram examinations for me. 
 I hereby consent to participate in this study on “A PROSPECTIVE STUDY 
ON MATERNAL & FETAL OUTCOME IN JAUNDICE 
COMPLICATING PREGNANCY”.  
Place:       Signature of the Patient:  
Date:       Address: 
Signature of the witness:    Signature of Investigator: 
 
  
 
MASTER CHART 
S.NO NAME AGE  IP.NO SE STATUS 
SAFE  
WATER OH WOG SYMPTOMS 
DURATION 
DAYS SIGNS 
S.BILURUBIN 
SGPT SGOT SAP TOTAL ID DIRECT 
1 SANDHYA 23 23253 4 US PRIMI 35 1,3,4,5 7 1 9.1 8.2 1.2 256 225 305 
2 BHUVANARATHA 26 25060 4 US PRIMI 38 1,3,4,7 5 1,3 7.2 5 2.2 187 176 143 
3 MUTHULAKSHMI 23 26485 5 US PRIMI 35 3,6,8, 6 1 7.9 2.6 5.3 90 52 278 
4 SARASWATHY 30 29136 3 S G2P1L1 38 2,3,5, 10 1,3 12.1 10.1 2 422 410 230 
5 JAYANTHI 21 30655 5 US PRIMI 35 2,3,5 5 1 6.5 3.5 3 298 202 397 
6 RAMANI 27 31900 5 US PRIMI 39 1,3,4,7, 3 1 8.4 6.2 2.2 206 194 457 
7 RANI 28 32217 4 S PRIMI 30 3,7,9, 1 1,5 2.1 1.1 1 392 354 722 
8 MANIMOZHI 33 22750 5 US G3P1L1A1 37 3,4,9 10 1,4,5 5 2.3 2.7 123 146 567 
9 SUGANTHI 23 23504 4 US PRIMI 20 1,3,4,5 12 1 13.2 7.2 6 252 207 352 
10 USHA 25 29863 4 US PRIMI 30 2,4,5 5 1 4.2 2.2 2 45 42 125 
11 BHUVANESHWARI 24 30832 5 US PRIMI 34 1,3,4,5 10 1 9.2 7 2.2 134 108 408 
12 LAKSHMI 32 30846 4 US G2P1L1 39 3,5,6 1 1 3.1 2.5 0.6 135 130 76 
13 POONGODI 32 32906 4 US G2P1L1 37 1,3,4,7 5 1,2 7.8 5.2 2.6 112 102 296 
14 KANIMOZHI 23 34108 5 US PRIMI 35 7,9 2 1 4 2.7 1.3 370 364 82 
15 MUTHAMMAL 27 34642 4 US G2P1L1 27 1,3,5 8 1 10.2 6.2 4 126 115 315 
16 MEENAKSHI 30 34496 4 S PRIMI 34 3,7 10 1 3 2.1 0.9 162 152 101 
17 NANDHINI 22 34856 4 US PRIMI 38 3,6,8 5 1 11 7 4 90 88 250 
18 RANI 26 35136 3 US PRIMI 37 1,3,5 3 1 8 5.2 2.8 112 98 276 
19 VALARMATHY 29 28302 5 US PRIMI 33 3,7 10 1 5.0 8.8 1.2 250 200 400 
20 LAKSHMI 30 36972 5 US G2A1 26 1,2,3,4,5 7 1,3 12 7 5 120 100 250 
21 GANGA 28 37242 4 US PRIMI 38 1,3,4,5 10 1 10 8.1 1.9 312 290 192 
22 REVATHY 24 37991 4 US PRIMI 35 1,3,4 3 1 6 4.1 2.9 275 260 472 
23 MAHESWARI 19 36814 5 US PRIMI 32 7,9 9 1 2.8 1.7 1.1 154 148 102 
24 NEELAVATHY 21 372 5 US G4A4 38 2,3,4 10 1,3 9.2 5.1 4.1 70 65 272 
25 GEETHA 29 1293 4 S PRIMI 27 4,7,9 2 1,4,5 3 1.2 1.8 104 100 700 
 
  
  
 
 
26 ANITHA 24 2163 5 US G2P1L1 40 1,3,4,5 4 1 9.2 5.2 4.0 387 356 112 
27 SUMITHRA 19 2089 5 US G2A1 38 2,3,4 3 1 6.2 4.2 2.0 216 174 256 
28 ASHA 20 3628 5 US PRIMI 37 1,3,4,5 7 1,3 7.2 4.2 3.0 612 596 250 
29 MANOMANI 28 4167 4 US PRIMI 3.7 2,3 3 1 5.0 3.0 2 42 40 112 
30 SATHYA 19 4231 4 US PRIMI 3.7 2,3,4,5 10 1 6 4.2 1.8 286 283 110 
31 SARASWATHY 32 5053 5 US G3A2 27 1,2,3,5 4 1,3 11.2 7.2 4 256 222 352 
32 JAYAKODI 26 3492 5 US G2P1L1 34 2,3,4,7 12 1 14 9.2 4.8 450 400 750 
33 JOTHIMADURI 24 1470 4 S G2P1L1 26 3,7,9 3 1 4 2.8 1.2 192 190 162 
34 LAKSHMI 35 37598 4 US PRIMI 9 7,2,7, 3 1 3 1.2 1.8 96 90 184 
35 KUPPU 25 8990 5 US G2A1 30 3,4,7,9 10 1,4,5 5 4.2 0.8 154 146 300 
36 DEEPA 19 10414 4 S G2P1L1 36 2,3,4,7 15   16 9.2 6.2 490 480 850 
37 SYED BEEVI 19 14081 4 US PRIMI 37 2,3,4,7 3 1,3 12.5 9 3.5 422 382 562 
38 RADHA 27 14190 5 US G2P1L1 26 1,4,5,7 10 1,3 5 2.7 2.3 156 152 140 
39 PUNITHA 24 16657 4 US G4P3L2 39 1,2,3 2 1 8 5.5 2.5 201 196 352 
40 REVATHY 28 17345 5 US G2P1L1 38 1,3,4,5 12 1 6.8 5.4 1.2 318 236 386 
41 CHITHRA 29 17477 5 US PRIMI 39 3,6,8 9 1,2 16.6 10 0.6 38 48 272 
42 BAKYALAKSHMI 20 19650 4 US PRIMI 26 1,2,3,5 10 1,3 11.2 6.2 5 198 102 356 
43 KELIDEVI 28 19674 5 US G3P1L1A1 31 3,7 3 1 6 4.1 1.9 304 381 174 
44 REKHA 21 21739 4 US PRIMI 33 2,6,8 7 1 9.2 5.2 4 297 280 412 
45 JEEVA 23 15325 5 US PRIMI 38 4,7,9 6 1,4 6.2 4.1 2.1 100 97 192 
46 MEERA 26 24211 5 US PRIMI 34 1,4,5,7 5 1 6.8 3.8 3 340 308 432 
47 SUMATHY 29 12542 4 US G2P1L1 36 1,3,5,7 11 1,3 15.1 9.2 5.9 320 311 740 
48 SIVARANJINI 20 13621 3 US PRIMI 37 1,3,5,7 5 1 12 7 5 562 540 823 
49 POONGODI 28 18254 4 VS G2P1L1 37 1,3,5,7 7 1 16 12 4 570 479 875 
50 LEELA 34 20127 3 S G2P1L1 9 3 10 1 5 4.1 0.9 45 42 105 
51 PACHIYAMMAL 22 24581 5 US G2P1L1 37 1,5,7 5 1 7 3.2 3.8 86 84 212 
 
  
  
 
 
S.NO PLT URINE ALB BS/BP LEPTO 
VIRAL  
MARKERS 
MODE OF 
DELIVERY COMPLICATION BLOOD FFB 
RECOVERY 
DEATH BABY OUTCOME 
      
APGAR 
<7 
DIAGNOSIS SEX MATURITY WT  
1 
2.1 - + - 
IGM ANTI 
HEV NVD -     R ALIVE F PT 1.9     YES HEPATITIS E 
2 
2.2 - + - HBS AG LSCS -   2 R ALIVE F T 2.9 NO HEPATITIS B 
3 2.1 - + -   NVD       R I Alive-Dead IIAlive-Dead F 
PT 
PT 
1.3 
1.2 YES IHP 
4 
1.8   + - 
IGM ANTI 
HEV NVD PPH 3 8 R DEAD F T 3 NO HEPATITIS E 
5 
2.0 - + - 
IGM ANTI 
HAV NVD       R ALIVE M PT 2.8 YES HEPATITIS A 
6 
2 - + - HBS AG OUTLET FORCEPS       R ALIVE F T 2.9 NO HEPATITIS B 
7 
0.8   +     NVD ABRUPTION     R DEAD F PT 1.5 NO HELLP 
8 
2.1   - - - LSCS       R ALIVE M T 2.9 NO CLD/PHT 
9 
1.9 - +   
IGM ANTI 
HEV           
DISCHARGED, LOST FOLLOW 
UP       NO HEPATITIS E 
10 
1.8 - + + - NVD HEPATAORENAL     R DEAD F PT 1.2 NO LEPTOSPTROSIS 
11 
1.7 - + - 
IGM ANTI 
HEV ASSISTED BREECH      5 R DEAD B PT 1.3 NO HEPATITIS E 
12 
1.6 - - - - NVD   2   R ALIVE B T 3.3 NO TRANFUSION REACTION 
13 
2.1   + - HBS AG LSCS       R ALIVE F T 3 NO HEPATITIS B 
14 
1.3 3+ + - - NVD ABRUPTION 2 10 R DEAD F PT 2.1 NO HELLP 
15 
2   +   
IGM ANTI 
HEV NVD         Alive -Dead F PT 1.2 YES HEPATITIS E 
16 
0.9 2+ + - - LSCS DIVC 2 12 R ALIVE B PT 2.1 NO HELLP 
17 
2.2 - + - - LSCS     2 R ALIVE F T 3 NO IHP 
18 
2   +     LSCS       R ALIVE M T 2.5 NO HEPATITIS B 
19 
0.5 3+ + - - NVD DIVC 6 20 DEATH DEAD F PT 1.2 NO HELLP 
20 
2   + -             
DISCHARGED, LOST FOLLOW 
UP       NO UNDETECTED 
21 
2.1 - + - HBS AG LSCS PPH 4 2 R ALIVE M T 3.1 NO HEPATITIS B 
22 
2 - +     NVD         ALIVE F PT 2.7 NO HEPATITIS E 
23 
1.1 2+ + - - NVD     4 R ALIVE F PT 2.2 NO HELLP 
24 
2.1 - + -   NVD     3 R ALIVE B T 3 NO HEPATITIS E 
25 
1.2 - + - -   OESOPHAGEAL VARICES 6 2 DEATH - -     NO CIRRHOSIS/ PHT 
  
 
26 
2   +   
IGM IANTI 
HEV NVD       R ALIVE B T 2.5 NO HEPATITIS E 
27 
1.9   +     NVD       R ALIVE B T 2.9 NO HEPATITIS A 
28 
2   +   
IGM ANTI 
HEV NVD PPH 4 8 R ALIVE B T 2.4 NO HEPATITIS E 
29 
2   +     NVD       R ALIVE G T 2.3 YES UNDETECTED 
30 
2   + - HBS AG NVD       R ALIVE G T 2.9 NO HEPATITIS E 
31 
1.5 1+ + -   NVD       R DEAD G PT 1 NO HEPATITIS B 
32 
2   + -   OUTLET FORCEPS HEPATIC ENCEPHALOPATHY  2 10 R ALIVE B PT 2.1 NO AFLP 
33 
0.8 2+ + -   NVD ABRUPTION 1 4   DEAD G PT 1.2 NO HELLP 
34 
1.8 - + - -           
DISCHARGED, LOST FOLLOW 
UP       NO HYPEREMESIS 
35 
1.7 - + - - NVD   2 6 R DEAD B PT 2.2 NO CIRRHOSIS/ PHT 
36 
1.0 - + - HBS AG NVD HEPATIC ENCEPHALOPATHY  1 10 R ALIVE B PT 2.3 YES HEPATITIS B 
37 
0.9 - + - - NVD DIVC 4 14 E ALIVE B T 3 NO AFLP 
38 
1.2 - + +   - - - - R         NO LEPTO SPIROSIS 
39 
2.1 - + - 
IGM ANTI 
HBV NVD - 2 4 R ALIVE B T 3.2 NO HEPATITIS B 
40 
1.5 - + - HBS AG NVD - - 6 R ALIVE G T 2.6 NO HEPATITIS B 
41 
2.5 - +   - LSCS -   4 R ALIVE B T 3.8 NO IHP 
42 
1.9 - + - HBS AG - -   -   
DISCHARGED, LOST FOLLOW 
UP       NO HEPATITIS B 
43 
1.2 2+ + - - NVD CHRONIC HT 1 10 R Alive-Dead G PT 1.4 YES HELLP 
44 
2.1 - + - - NVD HEPATORENAL - 4 R ALIVE B PT 1.6 YES AFLP 
45 
2.1 - - - - LSCS OESOPHAGEAL VARICEAS 1 4 R ALIVE B T 3.1 NO PORTAL VEIN THROMBOSIS 
46 
0.8 - +   - NVD HEPATIC ENCEPHALOPATHY      DEATH DEAD G PT 2.3 NO AFLP 
47 
1.6 - + - 
IGM ANTI 
HEV NVD   2 8 R DEAD G PT 2.6 NO HEPATITIS E 
48 
1.8 - + - HBS AG NVD   1 8 R DEAD G T 2.8 NO HEPATITIS B 
49 
1.9 - + - 
IGM ANTI 
HEV LSCS HEPATIC ENCEPHALOPATHY  2 8 R ALIVE B T 3.1 NO HEPATITIS E 
50 
1.2 - - -   ABORTION   2   R         NO HERE.SPHEROCYTOSIS 
51 
2.1 - + - 
IGM ANTI 
HAV LSCS PPH 4 4 R ALIVE G T 3 NO HEPATITIS A 
  
 
KEY TO MASTER CHART 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
OH   - Obstetric History 
WOG   - Weeks of gestation 
NVD   - Normal Vaginal delivery 
DIVC   - Disseminated Intravascular Coagulation 
IHP   - Intrahepatic cholestasis of Pregnancy 
AFLP   - Acute fatty liver of Pregnancy 
CLD   - Chronic liver disease 
PHT   - Portal hypertension 
PPH   - Post partum Hemorrhage 
SYMPTOMS 
      
        1 NAUSEA 
2 VOMITING 
3 HIGH COLOURED URINE 
4 LOSS OF APETITE 
5 FEVER 
6 ITCHING 
7 ABDOMINAL PAIN 
8 CLAY STOOLS 
9 ABDOMINAL DISTENTION 
SIGNS 
1 JAUNDICE 
2 SCRATCH MARKS 
3 HEPATOMEGALY 
4 SPLENOMEGALY 
5 ASCITES 
